<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38255418</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Children (Basel, Switzerland)</Title><ISOAbbreviation>Children (Basel)</ISOAbbreviation></Journal><ArticleTitle>Persisting Gastrointestinal Symptoms in Children with SARS-CoV-2: Temporal Evolution over 18 Months and Possible Role of Lactoferrin.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">105</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/children11010105</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="OBJECTIVE">Persisting gastrointestinal symptoms are reported to be relatively common in children with long COVID; however, their detailed characterization and long-term outcomes have not yet been described.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective study aiming to investigate the temporal evolution of gastrointestinal symptoms in children with SARS-CoV-2, from acute infection to 18-months follow-up. To further investigate possible therapeutic strategies, we evaluated the role of lactoferrin in improving gastrointestinal symptoms in these children, compared with those not treated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1224 patients (47.7% females) were included. Of these participants, 246 (19.8%) were vaccinated and 143 (11.5%) presented with comorbidities. A total of 175 patients (14.1%) presented gastrointestinal symptoms during acute infection, 54 (4.4%) at three months, 23 (1.9%) at six months, 6 (3.3%) at twelve months, and 2 (2.3%) at eighteen months follow-up. At six months follow-up, children who were treated with 3 months oral lactoferrin had less persisting symptoms compared to those who did not receive lactoferrin, although this difference was not statistically significant (three patients (25%) in the lactoferrin group vs. fourteen patients (33.3%) not treated, <i>p</i> = 0.73), probably due to the low number of patients with persisting GI symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GI symptoms are relatively common during acute SARS-CoV-2 infection in children, and a non-negligible proportion of these children reported persisting symptoms for up to 12-18 months after the acute infection. In addition, we found a trend even if statistically nonsignificant toward faster improvement of persisting gastrointestinal symptoms in children with long COVID treated with lactoferrin. Despite the limitations relating to the present study's design, given the significant burden of gastrointestinal symptoms in children with long COVID, our findings provide the basis to perform a prospective, placebo-controlled study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1142-6678</Identifier><AffiliationInfo><Affiliation>Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rainaldi</LastName><ForeName>Saveena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine and Surgery International Faculty, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dall'Ara</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medicine and Surgery International Faculty, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Rose</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morello</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buonsenso</LastName><ForeName>Danilo</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8567-2639</Identifier><AffiliationInfo><Affiliation>Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro di Salute Globale, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Children (Basel)</MedlineTA><NlmUniqueID>101648936</NlmUniqueID><ISSNLinking>2227-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">gastrointestinal symptoms</Keyword><Keyword MajorTopicYN="N">lactoferrin</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post COVID condition (PCC)</Keyword></KeywordList><CoiStatement>This study is part of a larger study founded with a Pfizer non-competitive grant granted to D.B., for the definition of long-term outcomes of SARS-CoV-2 infection in children. The funder had no role in the development of the project nor in the interpretation of results. Other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38255418</ArticleId><ArticleId IdType="pmc">PMC10814461</ArticleId><ArticleId IdType="doi">10.3390/children11010105</ArticleId><ArticleId IdType="pii">children11010105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A., Desai A.D., Wan E.Y. Post-COVID-19 Condition. Annu. Rev. Med. 2023;74:55&#x2013;64. doi: 10.1146/annurev-med-043021-030635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-043021-030635</ArticleId><ArticleId IdType="pubmed">35914765</ArticleId></ArticleIdList></Reference><Reference><Citation>Huerne K., Filion K.B., Grad R., Ernst P., Gershon A.S., Eisenberg M.J. Epidemiological and clinical perspectives of long COVID syndrome. Am. J. Med. Open. 2023;9:100033. doi: 10.1016/j.ajmo.2023.100033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajmo.2023.100033</ArticleId><ArticleId IdType="pmc">PMC9846887</ArticleId><ArticleId IdType="pubmed">36685609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y.-B., Zeng N., Yuan K., Tian S.-S., Yang Y.-B., Gao N., Chen X., Zhang A.-Y., Kondratiuk A.L., Shi P.-P., et al. Prevalence and risk factor for long COVID in children and adolescents: A meta-analysis and systematic review. J. Infect. Public Health. 2023;16:660&#x2013;672. doi: 10.1016/j.jiph.2023.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.03.005</ArticleId><ArticleId IdType="pmc">PMC9990879</ArticleId><ArticleId IdType="pubmed">36931142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P., Jat K.R. Post-COVID-19 Sequelae in Children. Indian J. Pediatr. 2023;90:605&#x2013;611. doi: 10.1007/s12098-023-04473-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12098-023-04473-4</ArticleId><ArticleId IdType="pmc">PMC9992903</ArticleId><ArticleId IdType="pubmed">36884145</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotugno N., Amodio D., Buonsenso D., Palma P. Susceptibility of SARS-CoV2 infection in children. Eur. J. Pediatr. 2023;182:4851&#x2013;4857. doi: 10.1007/s00431-023-05184-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-023-05184-w</ArticleId><ArticleId IdType="pmc">PMC10640404</ArticleId><ArticleId IdType="pubmed">37702769</ArticleId></ArticleIdList></Reference><Reference><Citation>Meringer H., Wang A., Mehandru S. The Pathogenesis of Gastrointestinal, Hepatic, and Pancreatic Injury in Acute and Long Coronavirus Disease 2019 Infection. Gastroenterol. Clin. N. Am. 2023;52:1&#x2013;11. doi: 10.1016/j.gtc.2022.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gtc.2022.12.001</ArticleId><ArticleId IdType="pmc">PMC9721275</ArticleId><ArticleId IdType="pubmed">36813418</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Morrone M.C., Patrono C., Santoro M.G., Schiaffino S., Remuzzi G., Bussolati G., Cappuccinelli P. Long Covid: Where we stand and challenges ahead. Cell Death Differ. 2022;29:1891&#x2013;1900. doi: 10.1038/s41418-022-01052-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-01052-6</ArticleId><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;&#x2014;A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol. Res. Perspect. 2022;10:e00911. doi: 10.1002/prp2.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.911</ArticleId><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W.-J., Hui C.K.M., Hull J.H., Birring S.S., McGarvey L., Mazzone S.B., Chung K.F. Confronting COVID-19-associated cough and the post-COVID syndrome: Role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir. Med. 2021;9:533&#x2013;544. doi: 10.1016/S2213-2600(21)00125-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00125-9</ArticleId><ArticleId IdType="pmc">PMC8041436</ArticleId><ArticleId IdType="pubmed">33857435</ArticleId></ArticleIdList></Reference><Reference><Citation>Astin R., Banerjee A., Baker M.R., Dani M., Ford E., Hull J.H., Lim P.B., McNarry M., Morten K., O&#x2019;Sullivan O., et al. Long COVID: Mechanisms, risk factors and recovery. Exp. Physiol. 2023;108:12&#x2013;27. doi: 10.1113/EP090802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/EP090802</ArticleId><ArticleId IdType="pmc">PMC10103775</ArticleId><ArticleId IdType="pubmed">36412084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Zhang L., Wang Y., Dai T., Qin Z., Zhou F., Zhang L. Alterations in microbiota of patients with COVID-19: Potential mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 2022;7:143. doi: 10.1038/s41392-022-00986-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00986-0</ArticleId><ArticleId IdType="pmc">PMC9052735</ArticleId><ArticleId IdType="pubmed">35487886</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello R., De Rose C., Cardinali S., Valentini P., Buonsenso D. Lactoferrin as Possible Treatment for Chronic Gastrointestinal Symptoms in Children with Long COVID: Case Series and Literature Review. Children. 2022;9:1446. doi: 10.3390/children9101446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children9101446</ArticleId><ArticleId IdType="pmc">PMC9600357</ArticleId><ArticleId IdType="pubmed">36291381</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Di Gennaro L., De Rose C., Morello R., D&#x2019;Ilario F., Zampino G., Piazza M., Boner A.L., Iraci C., O&#x2019;Connell S., et al. Long-term outcomes of pediatric infections: From traditional infectious diseases to long Covid. Future Microbiol. 2022;17:551&#x2013;571. doi: 10.2217/fmb-2022-0031.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2022-0031</ArticleId><ArticleId IdType="pmc">PMC8910780</ArticleId><ArticleId IdType="pubmed">35264003</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  A Clinical Case Definition for Post COVID-19 Condition in Children and Adolescents by Expert Consensus, 16 February 2023.  [(accessed on 6 November 2023)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1.</Citation></Reference><Reference><Citation>Morello R., Mariani F., Mastrantoni L., De Rose C., Zampino G., Munblit D., Sigfrid L., Valentini P., Buonsenso D. Risk factors for post-COVID-19 condition (Long Covid) in children: A prospective cohort study. EClinicalMedicine. 2023;59:101961. doi: 10.1016/j.eclinm.2023.101961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101961</ArticleId><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoxha B., Hodaj A. Potential Role of Lactoferrin and Heparin in COVID-19: A Review. Eur. Sci. J. ESJ. 2021;17:14. doi: 10.19044/esj.2021.v17n14p14.</Citation><ArticleIdList><ArticleId IdType="doi">10.19044/esj.2021.v17n14p14</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolat E., Eker F., Kaplan M., Duman H., Arslan A., Sarita&#x15f; S., &#x15e;ahuto&#x11f;lu A.S., Karav S. Lactoferrin for COVID-19 prevention, treatment, and recovery. Front. Nutr. 2022;9:992733. doi: 10.3389/fnut.2022.992733.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.992733</ArticleId><ArticleId IdType="pmc">PMC9676636</ArticleId><ArticleId IdType="pubmed">36419551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwirzitz A., Reiter M., Skrabana R., Ohradanova-Repic A., Majdic O., Gutekova M., Cehlar O., Petrov&#x10d;&#xed;kov&#xe1; E., Kutejova E., Stanek G., et al. Lactoferrin is a natural inhibitor of plasminogen activation. J. Biol. Chem. 2018;293:8600&#x2013;8613. doi: 10.1074/jbc.RA118.003145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.003145</ArticleId><ArticleId IdType="pmc">PMC5986228</ArticleId><ArticleId IdType="pubmed">29669808</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., Khan M.A., Putrino D., Woodcock A., Kell D.B., Pretorius E. Long COVID: Pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metab. 2023;34:321&#x2013;344. doi: 10.1016/j.tem.2023.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2023.03.002</ArticleId><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="pubmed">37080828</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., Kell D.B. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro L., Valentini P., Sorrentino S., Ferretti M.A., De Candia E., Basso M., Lancellotti S., De Cristofaro R., De Rose C., Mariani F., et al. Extended coagulation profile of children with Long Covid: A prospective study. Sci. Rep. 2022;12:18392. doi: 10.1038/s41598-022-23168-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23168-y</ArticleId><ArticleId IdType="pmc">PMC9626616</ArticleId><ArticleId IdType="pubmed">36319840</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Martino L., Morello R., Mariani F., Fearnley K., Valentini P. Viral persistence in children infected with SARS-CoV-2: Current evidence and future research strategies. Lancet Microbe. 2023;4:e745&#x2013;e756. doi: 10.1016/S2666-5247(23)00115-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00115-5</ArticleId><ArticleId IdType="pmc">PMC10292824</ArticleId><ArticleId IdType="pubmed">37385286</ArticleId></ArticleIdList></Reference><Reference><Citation>Salaris C., Scarpa M., Elli M., Bertolini A., Guglielmetti S., Pregliasco F., Blandizzi C., Brun P., Castagliuolo I. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro. Nutrients. 2021;13:328. doi: 10.3390/nu13020328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13020328</ArticleId><ArticleId IdType="pmc">PMC7911668</ArticleId><ArticleId IdType="pubmed">33498631</ArticleId></ArticleIdList></Reference><Reference><Citation>Matino E., Tavella E., Rizzi M., Avanzi G.C., Azzolina D., Battaglia A., Becco P., Bellan M., Bertinieri G., Bertoletti M., et al. Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial. Nutrients. 2023;15:1285. doi: 10.3390/nu15051285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15051285</ArticleId><ArticleId IdType="pmc">PMC10005739</ArticleId><ArticleId IdType="pubmed">36904283</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi G.F., Carota G., Castracani C.C., Spampinato M., Manti S., Papale M., Di Rosa M., Barbagallo I., Leonardi S. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature. Int. J. Mol. Sci. 2021;22:2465. doi: 10.3390/ijms22052465.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052465</ArticleId><ArticleId IdType="pmc">PMC7957644</ArticleId><ArticleId IdType="pubmed">33671104</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvard Health Publishing  Can Long COVID Affect the Gut?  [(accessed on 9 January 2024)].  Available online:  https://www.health.harvard.edu/blog/can-long-covid-affect-the-gut-202303202903.</Citation></Reference><Reference><Citation>Einerhand A.W.C., van Loo-Bouwman C.A., Weiss G.A., Wang C., Ba G., Fan Q., He B., Smit G. Can Lactoferrin, a Natural Mammalian Milk Protein, Assist in the Battle against COVID-19? Nutrients. 2022;14:5274. doi: 10.3390/nu14245274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14245274</ArticleId><ArticleId IdType="pmc">PMC9782828</ArticleId><ArticleId IdType="pubmed">36558432</ArticleId></ArticleIdList></Reference><Reference><Citation>Karav S., German J.B., Rouquie C., le Parc A., Barile D. Studying Lactoferrin N-Glycosylation. Int. J. Mol. Sci. 2017;18:870. doi: 10.3390/ijms18040870.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18040870</ArticleId><ArticleId IdType="pmc">PMC5412451</ArticleId><ArticleId IdType="pubmed">28425960</ArticleId></ArticleIdList></Reference><Reference><Citation>Artym J., Zimecki M. Antimicrobial and Prebiotic Activity of Lactoferrin in the Female Reproduc-tive Tract: A Comprehensive Review. Biomedicines. 2021;9:1940. doi: 10.3390/biomedicines9121940.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9121940</ArticleId><ArticleId IdType="pmc">PMC8699013</ArticleId><ArticleId IdType="pubmed">34944756</ArticleId></ArticleIdList></Reference><Reference><Citation>Liepke C., Adermann K., Raida M., M&#xe4;gert H.J., Forssmann W.G., Zucht H.D. Human milk provides peptides highly stimulating the growth of bifidobacteria. Eur. J. Biochem. 2002;269:712&#x2013;718. doi: 10.1046/j.0014-2956.2001.02712.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0014-2956.2001.02712.x</ArticleId><ArticleId IdType="pubmed">11856332</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico F., Decembrino N., Muratore E., Turroni S., Muggeo P., Mura R., Perruccio K., Vitale V., Zecca M., Prete A., et al. Oral Lactoferrin Supplementation during Induction Chemotherapy Promotes Gut Microbiome Eubiosis in Pediatric Patients with Hematologic Malignancies. Pharmaceutics. 2022;14:1705. doi: 10.3390/pharmaceutics14081705.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14081705</ArticleId><ArticleId IdType="pmc">PMC9416448</ArticleId><ArticleId IdType="pubmed">36015331</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., Wan Y., Chung A.C.K., Cheung C.P., Chen N., et al. Alterations in Gut Microbiota of Patients with COVID-19 during Time of Hospitalization. Gastroenterology. 2020;159:944&#x2013;955.e948. doi: 10.1053/j.gastro.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C.Y., Zhang F., Liu Q., Li A.Y.L., Chung A.C.K., Cheung C.P., Tso E.Y.K., Fung K.S.C., et al. Gut Microbiota Composition Reflects Disease Severity and Dysfunctional Immune Responses in Patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Gu S., Chen Y., Lu H., Shi D., Guo J., Wu W.R., Yang Y., Li Y., Xu K.J., et al. Letter: Six-Month Follow-up of Gut Microbiota Richness in Patients with COVID-19. Gut. 2022;71:222. doi: 10.1136/gutjnl-2021-324090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324090</ArticleId><ArticleId IdType="pmc">PMC8666823</ArticleId><ArticleId IdType="pubmed">33833065</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira G.L.V., Oliveira C.N.S., Pinzan C.F., de Salis L.V.V., Cardoso C.R.d.B. Microbiota Modulation of the Gut-Lung Axis in COVID-19. Front. Immunol. 2021;12:635471. doi: 10.3389/fimmu.2021.635471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.635471</ArticleId><ArticleId IdType="pmc">PMC7945592</ArticleId><ArticleId IdType="pubmed">33717181</ArticleId></ArticleIdList></Reference><Reference><Citation>Buccigrossi V., de Marco G., Bruzzese E., Ombrato L., Bracale I., Polito G., Guarino A. Lac-toferrin Induces Concentration Dependent Functional Modulation of Intestinal Proliferation and Differentiation. Pediatr. Res. 2007;61:410&#x2013;414. doi: 10.1203/pdr.0b013e3180332c8d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/pdr.0b013e3180332c8d</ArticleId><ArticleId IdType="pubmed">17515863</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost F.J., Saris W., Brummer R.-J. Original Communication Recombinant Human Lactoferrin Ingestion Attenuates. Indomethacin-Induced Enteropathy In Vivo in Healthy Volunteers. Eur. J. Clin. Nutr. 2003;57:1579&#x2013;1585. doi: 10.1038/sj.ejcn.1601727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejcn.1601727</ArticleId><ArticleId IdType="pubmed">14647223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker L.M., Gilboa T., Ogata A.F., Senussi Y., Lazarovits R., Boribong B.P., Bartsch Y.C., Loiselle M., Rivas M.N., Porritt R.A., et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J. Clin. Investig. 2021;131:e149633. doi: 10.1172/JCI149633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149633</ArticleId><ArticleId IdType="pmc">PMC8279585</ArticleId><ArticleId IdType="pubmed">34032635</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Covid: Drug Trial Results to Watch in 2022 and Beyond.  [(accessed on 6 November 2023)].  Available online:  https://www.clinicaltrialsarena.com/features/long-covid-19-drug-trial-results-to-watch-in-2022/</Citation></Reference><Reference><Citation>Ianiro G., Niro A., Rosa L., Valenti P., Musci G., Cutone A. To Boost or to Reset: The Role of Lactoferrin in Energy Metabolism. Int. J. Mol. Sci. 2023;24:15925. doi: 10.3390/ijms242115925.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242115925</ArticleId><ArticleId IdType="pmc">PMC10650157</ArticleId><ArticleId IdType="pubmed">37958908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling C.-J., Xu J.-Y., Li Y.-H., Tong X., Yang H.-H., Yang J., Yuan L.-X., Qin L.-Q. Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis. Food Funct. 2019;10:7299&#x2013;7307. doi: 10.1039/C9FO01616C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9FO01616C</ArticleId><ArticleId IdType="pubmed">31626262</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterino M., Gelzo M., Sol S., Fedele R., Annunziata A., Calabrese C., Fiorentino G., D&#x2019;Abbraccio M., Dell&#x2019;Isola C., Fusco F.M., et al. Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. Sci. Rep. 2021;11:2941. doi: 10.1038/s41598-021-82426-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-82426-7</ArticleId><ArticleId IdType="pmc">PMC7859398</ArticleId><ArticleId IdType="pubmed">33536486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Shu T., Yang X., Song J.-X., Zhang M., Yao C., Liu W., Huang M., Yu Y., Yang Q., et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl. Sci. Rev. 2020;7:1157&#x2013;1168. doi: 10.1093/nsr/nwaa086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa086</ArticleId><ArticleId IdType="pmc">PMC7197563</ArticleId><ArticleId IdType="pubmed">34676128</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorucci S., Urbani G., Biagioli M., Sepe V., Distrutti E., Zampella A. Bile acids and bile acid activated receptors in the treatment of COVID-19. Biochem. Pharmacol. 2023:115983. doi: 10.1016/j.bcp.2023.115983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2023.115983</ArticleId><ArticleId IdType="pubmed">38081371</ArticleId></ArticleIdList></Reference><Reference><Citation>Spick M., Campbell A., Baricevic-Jones I., von Gerichten J., Lewis H.-M., Frampas C.F., Longman K., Stewart A., Dunn-Walters D., Skene D.J., et al. Multi-Omics Reveals Mechanisms of Partial Modulation of COVID-19 Dysregulation by Glucocorticoid Treatment. Int. J. Mol. Sci. 2022;23:12079. doi: 10.3390/ijms232012079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232012079</ArticleId><ArticleId IdType="pmc">PMC9602480</ArticleId><ArticleId IdType="pubmed">36292938</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>